1-((beta-mercapto-beta)beta cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-9-des-gly-arginine vasopressin has been researched along with Acquired Nephrogenic Diabetes Insipidus in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angers, S; Arthus, MF; Bernier, V; Bichet, DG; Bouvier, M; Laperrière, A; Lonergan, M; Morello, JP; Morin, D; Petäjä-Repo, U; Salahpour, A | 1 |
1 other study(ies) available for 1-((beta-mercapto-beta)beta cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-9-des-gly-arginine vasopressin and Acquired Nephrogenic Diabetes Insipidus
| Article | Year |
|---|---|
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Cell Line; Cell Membrane; COS Cells; Diabetes Insipidus, Nephrogenic; Flow Cytometry; Humans; Intracellular Fluid; Molecular Chaperones; Morpholines; Mutagenesis; Protein Folding; Pyrroles; Receptors, Vasopressin; Spiro Compounds | 2000 |